Cetera Investment Advisers Exelixis, Inc. Transaction History
Cetera Investment Advisers
- $45.9 Billion
- Q4 2024
A detailed history of Cetera Investment Advisers transactions in Exelixis, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 116,674 shares of EXEL stock, worth $4.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
116,674
Previous 118,354
1.42%
Holding current value
$4.32 Million
Previous $3.07 Million
26.51%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding EXEL
# of Institutions
566Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.24 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$868 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$566 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$422 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...